32 reports

  • Liver Cancer Overview
  • III. LIVER CANCER TREATMENT DRUGS

The liver cancer treatment drugs industry is one of key sectors of Chinese industry and has become more and more important.

  • Liver Cancer
  • China
  • Demand
  • Novartis AG
  • Sanofi-Synthelabo Inc.
  • Liver Cancer Overview
  • IV. LIVER CANCER TREATMENT DRUGS PRODUCTION AND

INTRODUCTION Chapter I Table ##: Economic Outlook Summary (Billion Yuan) Chart ##: Economic Outlook Summary (Billion Yuan) Chapter I INTRODUCTION The current market for liver cancer treatment drugs in China is growing rapidly.

  • Liver Cancer
  • China
  • Demand
  • Trade
  • Hainan Haiyao Company Limited
  • Liver Cancer Treatment Drugs Companies in China
  • Liver Cancer Treatment Drugs Industry Structure

The liver cancer treatment drugs industry is one of key sectors of Chinese industry and has become more and more important.

  • Liver Cancer
  • China
  • Biostar Pharmaceuticals, Inc.
  • Novartis AG
  • Sanofi-Synthelabo Inc.

Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type, By Region And Segment Forecasts, 2019 - 2025 Chapter ## Methodology and Scope ##. ## Research Methodology ##. ##. ## Information Procurement ##. ## Information or Data Analysis ##. ## Research Scope and Ass

  • Cancer
  • Liver Cancer
  • North America
  • United States
  • Market Size

Liver Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class, By Country And Segment Forecasts, 2016 - 2022 Chapter ## Research Methodology ##. ##.

  • Cancer
  • Liver Cancer
  • United Kingdom
  • United States
  • Forecast
  • FEATURES OF LIVER CANCER PATIENTS
  • Incidence of Liver Cancer, females (000s)

HPB. 2005; ##(##):##-##. ##.

  • Cancer
  • Hepatitis
  • Liver Cancer
  • Pathology

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Liver Cancer
  • France
  • United States
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Liver Cancer
  • France
  • Germany
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • United States
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • Japan
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • Italy
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • Germany
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • France
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • United Kingdom
  • Market Shares
  • Market Size

Hepatoma Liver Cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Liver Cancer
  • Spain
  • Market Shares
  • Market Size
  • EARLYCDT - LIVER CANCER KIT - PRODUCT DESCRIPTION
  • EARLYCDT - LIVER CANCER KIT - PRODUCT STATUS

HCC is the most common form of liver cancer and causes up to one million deaths globally every year.

  • Biomarker
  • Clinical Trial
  • Hepatitis
  • Liver Cancer
  • Pfizer Inc.
  • 7.5 United States - Liquid Biopsy Liver Cancer Treatment Monitoring
  • 6.5 United States - Liquid Biopsy Liver Cancer Screening Potential

Liver Cancer The Top ## Cancer Segments covered are: ##.

  • Liver Cancer
  • North America
  • United States
  • Forecast
  • Biocept, Inc.
  • 4.4.1 United States - Liver Cancer Biopsy Test Market & Forecast
  • 4.4.2 United States - Liver Cancer Biopsy Test Volume & Forecast

Surgical Biopsy ##.

  • Biopsy
  • Liver Cancer
  • Prostate Cancer
  • United States
  • Forecast

The report focuses on drugs and therapies being evaluated for Metastatic Liver Cancer treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Cancer
  • Clinical Trial
  • Drug Development
  • Liver Cancer
  • Pathology

Metastatic Liver Cancer - Pipeline Insight, 2019 ##.

  • Liver Cancer
  • Therapy
  • Symptoms of Liver Cancer
  • Liver Cancer, Molecular Target Category

A poor quality diet, particularly one characterized by high alcohol consumption, is another significant risk factor in liver cancer.

  • Cancer
  • Hepatitis
  • Liver Cancer
  • Pathology
  • Therapy

Liver cancer Pipeline Highlights – 2017 ##.

  • Cancer
  • Liver Cancer
  • United States
  • Product Initiative

Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase ##, Preclinical and Discovery stages comprises ##, ##, ##, ##, ## and ## molecules, respectively.

  • Cancer
  • Liver Cancer
  • Pathology
  • Pharmaceutical
  • Therapy

Liver Cancer - Pipeline Review, H## 2016 Table of Contents Table of Contents ## Introduction ## Liver Cancer Overview ## Therapeutics Development ## Liver Cancer - Therapeutics under Development by Companies ## Liver Cancer - Therapeutics under Investigation by Unive

  • Cancer
  • Liver Cancer
  • Pathology
  • Pharmaceutical
  • Therapy
  • SEP 04, 2018: TOP LINE RESULTS OF THE NAMODENOSON PHASE II ADVANCED LIVER CANCER TRIAL EXPECTED BY END OF YEAR
  • JUL 02, 2018: DRUGS WITH MECHANISM OF ACTION UTILIZED BY NAMODENOSON ARE RECOMMENDED BY LEADING U.S. RESEARCHERS TO BE DEVELOPED TO COMBAT LIVER CANCER

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ## and ## respectively.

  • Liver Cancer
  • Therapy
  • World
  • Product Initiative
  • Can-Fite BioPharma Ltd.
  • NBTXR3 - LIVER CANCER
  • NBTXR3 - LIVER CANCER PRODUCT OVERVIEW

## Liver Cancer ## Lung Cancer ## Pancreatic Cancer ## Prostate Cancer ## Rectal Diseases ## Soft Tissue Cancer ## Nanobiotix SA Ongoing Clinical Trials by Trial Status Ongoing, Recruiting ## Planned ## Ongoing, not Recruiting

  • Liver Cancer
  • Neck Cancer
  • United States
  • Product Initiative
  • Nanobiotix
  • Clinical Trial profile. 65 Trial Title
  • Clinical Trial profile. 78 Trial Title

Bonafede / PosterDate/ Time (EDT): Oct. ##, 2017, ##:## - ##:## p. m. Location/ Session: Clinical Liver Cancer, Hall D About OpdivoOpdivo is a programmed death-## (PD-##) immune checkpoint inhibitor that is designed to uniquely harness the body' s own immune sy

  • Hepatitis
  • Hospital
  • Liver Cancer
  • World
  • Product Initiative
  • SURVIVIN-IGM KIT - LIVER CANCER
  • COMPLEXIMA HCC BIOCHIP - LIVER CANCER

Liver Cancer ## Breast Cancer ## Colorectal Cancer ## Esophageal Cancer ## Cervical Cancer ## Lung Cancer ## Non-Alcoholic Steato-Hepatitis (NASH) ## Prostate Cancer ## Scleroderma ## Indication No of Products XEPTAGEN SPA - PIPELINE ANALYSIS OVE

  • Bioinformatics
  • Cancer
  • In Vitro Diagnostics
  • Liver Cancer
  • APR 27, 2017: FDA EXPANDS APPROVED USE OF STIVARGA TO TREAT LIVER CANCER
  • JUN 23, 2017: BAYER RECEIVES POSITIVE CHMP OPINION FOR REGORAFENIB FOR THE SECOND-LINE SYSTEMIC TREATMENT OF LIVER CANCER

" Liver cancer is one of the leading cancer-related causes of death in Japan.

  • Liver Cancer
  • Oncology
  • World
  • Product Initiative
  • Exelixis, Inc.
  • LIVER CANCER (2/2)
  • 4.5 LIVER CANCER HOLDS THE LARGEST SHARE IN TUMOR ABLATION MARKET IN 2016

EDAP TMS launched the Focal One in the global market.

  • Liver Cancer
  • North America
  • United States
  • World
  • SonaCare Medical, LLC